Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ACTRIMS 2024 | An update on research in BTK inhibitors for the treatment of MS

Barry Singer, MD, The MS Center for Innovations in Care, St. Louis, MO, gives an update on the current research into BTK inhibitors for the treatment of relapsing multiple sclerosis (MS). He mentions the Phase III evolutionRMS1 (NCT04338022) and evolutionRMS2 (NCT04338061) trials investigating evobrutinib versus teriflunomide. The trial found similar relapse rates and biomarker levels between the two agents, indicating that evobrutinib is not superior to teriflunomide. Dr Singer also mentions tolebrutinib, which has been evaluated for its ability to reduce paramagnetic rim lesions, which are iron deposits left behind after myelin is broken down. However, this study found negative results. This interview took place during the annual ACTRIMS Forum 2024.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.